BriaCell announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with #metastaticbreastcancer treated with immune based therapies including the BriaCell regimen at the #ESMO26 Congress, taking place October 23-27, 2026 in Madrid, Spain.

The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study. For additional presentation information: https://bit.ly/4yGWuOd $BCTX $BCTXL